Tehila Ben-moshe

Tehila Ben-Moshe is the CEO and VP R&D of cCAM Biotherapeutics, a company located in the north of Israel and dedicated to the development of novel immuno therapies to treat cancer. Dr. Ben Moshe is managing the company from day one and brought early stage Incubator Company from inception to successful POC and clinical trial in cancer patient.

Dr. Ben Moshe is responsible for all daily activities of the company (14 employees) including R&D, Regulation, IP, HR, legal and financial activities. She is also was leading the business development communications with potential collaborators including scientific, operational and corporate due diligence processes. The company was recently acquired by Merck Sharp and Dohme Corp.

Prior to that Dr. Ben Moshe was member of the R&D broad management team of Protalix BioTherapeutics (AMEX: PLX), where she managed the preclinical development of recombinant proteins and was involved in regulatory filing and clinical trials.

Dr Ben-Moshe holds a BSc in Biochemistry and Food Biotechnology from Faculty of Agriculture, The Hebrew University of Jerusalem (HUJI), MSc in Neuroimmunology, from Bar Ilan University and a Ph.D in Biochemistry from Weizmann Institute of Science- Rehovot. She did an independent scientific training as a visiting scientist and as post doc in Melbourne University (WEHI; Australia) and at the Hadassah medical school (Jerusalem).